BioStock: Biosergen's CEO - "this is a global health threat and it needs attention"

The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation have announced a USD 300 million initiative to support solutions for major global health threats, including infectious diseases. BioStock spoke with Tine Kold Olesen, CEO at Biosergen, a Swedish biotech developing drugs targeting life-threatening fungal infections, to get her take on this partnership and how it might impact small drug developers like Biosergen. 

Read the article at biostock.se:

Biosergen's CEO: "this is a global health threat and it needs attention" - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/